SCHEMBL265884

SCHEMBL265884

CCN(CC)CCN(C)Cc1ccc(C(=O)Nc2ccc(Br)cc2C(=O)NN=Cc2ccc(C)c(C)c2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.41
ALDH1A1 P00352 3/20 0.41
F10 P00742 9/20 0.40
SMN1; SMN2 Q16637 3/20 0.39
RAB9A P51151 2/20 0.39
POLB P06746 4/20 0.39
CTDSP1 Q9GZU7 2/20 0.39
PLEC Q15149 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
MAPT P10636 5/20 0.38
HPGD P15428 4/20 0.38
NPC1 O15118 1/20 0.38
HIF1A Q16665 1/20 0.38
MEN1 O00255 3/20 0.37
KMT2A Q03164 3/20 0.37
PKM P14618 1/20 0.37
ALOX12 P18054 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
LMNA P02545 1/20 0.37
BLM P54132 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL265883 1.00 KDM4E (0.41) KDM4EALDH1A1F10SMN1; SMN2RAB9A
SCHEMBL267710 0.92 ALDH1A1 (0.42) KDM4EALDH1A1F10SMN1; SMN2RAB9A
SCHEMBL267711 0.92 ALDH1A1 (0.42) KDM4EALDH1A1F10SMN1; SMN2RAB9A
SCHEMBL266332 0.90 SMN1; SMN2 (0.53) KDM4EALDH1A1F10SMN1; SMN2RAB9A
SCHEMBL266333 0.90 SMN1; SMN2 (0.53) KDM4EALDH1A1F10SMN1; SMN2RAB9A
SCHEMBL266481 0.90 MEN1 (0.49) KDM4EALDH1A1F10SMN1; SMN2RAB9A
SCHEMBL266480 0.90 MEN1 (0.49) KDM4EALDH1A1F10SMN1; SMN2RAB9A
SCHEMBL265464 0.88 KDM4E (0.53) KDM4EALDH1A1F10SMN1; SMN2RAB9A
SCHEMBL265463 0.88 KDM4E (0.53) KDM4EALDH1A1F10SMN1; SMN2RAB9A
SCHEMBL266945 0.88 SLC34A2 (0.44) KDM4EALDH1A1F10SMN1; SMN2RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same KIRIN BEER KABUSHIKI KAISHA (JP) 2006-09-28 US disclosed
EP-1614676-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KIRIN BEER KABUSHIKI KAISHA (JP) 2006-01-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same SLC10A6, SLC7A1, SLC10A1 KDM4E 4468/4885ALDH1A1 3022/4885F10 188/4885
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME SLC34A1, SLC34A2, SLC20A2 KDM4E 4535/4885ALDH1A1 2872/4885F10 338/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.